In final draft guidance NICE recommended use of Xarelto at a dose of 2.5mg daily combined with aspirin, as an option for preventing atherothrombotic events in adults with coronary artery disease ...

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagulant.